Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia

Psychiatry Research - Neuroimaging

Volumn 92, Issue 1, 1999, Pages 33-44

  Lavalaye, Jules ^a,b   Linszen, Donald H ^a   Booij, Jan ^a,b   Reneman, Liesbeth ^a,b   Gersons, Berthold P R ^a   Van Royen, Eric A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Graduate School of Neurosciences   (Netherlands)

Author keywords

Antipsychotic agents; Benzamides; Brain; Human; Prolactin; Single photon emission computed tomography

Indexed keywords

BENZAMIDE DERIVATIVE; BENZODIAZEPINE; DOPAMINE 2 RECEPTOR; IODINE 123; OLANZAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZODIAZEPINE DERIVATIVE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; NEUROLEPTIC AGENT; PIRENZEPINE; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; MENTAL DISEASE; NEURORADIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; BRAIN MAPPING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCINTISCANNING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BENZODIAZEPINES; BRAIN; BRAIN MAPPING; CONTRAST MEDIA; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 0033536732     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(99)00032-3     Document Type: Article

References (41)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. American Journal of Psychiatry. 155:1998;761-767.
2. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. 1994;American Psychiatric Association Press, Washington, D.C.
3. Barnes T.R. A rating scale for drug-induced akathisia. British Journal of Psychiatry. 154:1989;672-676.
4. Beasley C.M.J., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S.H. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 14:1996;111-123.
5. Borison R.L., Pathiraja A.P., Diamond B.I., Meibach R.C. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin. 28:1992;213-218.
6. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartelomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America. 94:1997;2569-2574.
7. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
8. Carlsson A. Occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacology Reviews. 11:1959;300-304.
9. Coccaro E.F., Kavoussi R.J., Oakes M., Cooper T.B., Hauger R. 5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to D-fenfluramine challenge in physically healthy human subjects. Psychopharmacology. 126:1996;24-30.
10. 2 receptor occupancy in risperidone-treated schizophrenic patients. Journal of Nuclear Medicine. 39:1998;1138-1142.
11. 11C]raclopride. Archives of General Psychiatry. 47:1990;213-219.
12. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Archives of General Psychiatry. 49:1992;538-544.
13. Gervin M., Browne S., Lane A., Clarke M., Waddington J.L., Larkin C., O'Callaghan E. Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. American Journal of Psychiatry. 155:1998;1202-1206.
14. Hietala J., Kuoppamaki M., Nagren K., Lehikoinen P., Syvalahti E. Effects of lorazepam administration on striatal dopamine D2 receptor binding characteristics in man - a positron emission tomography study. Psychopharmacology. 132:1997;361-365.
15. Kapur S. A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Molecular Psychiatry. 3:1998;135-140.
16. Kapur S., Remington G., Zipursky R.B., Wilson A.A., Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sciences. 57:1995;L103-L107.
17. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. American Journal of Psychiatry. 155:1998;921-928.
18. 2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. American Journal of Psychiatry. 156:1999;286-293.
19. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 13:1986;261-276.
20. 2 receptor occupancy levels. Psychiatry Research: Neuroimaging. 75:1997;91-101.
21. Küfferle B., Brücke T., Topitz-Schratzberger A., Tauscher J., Gossler R., Vesely C., Asenbaum S., Podreka I., Kasper S. Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. Psychiatry Research: Neuroimaging. 68:1996;23-30.
22. Laruelle M., Abi-Dargham A., van Dyck H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America. 93:1996;9235-9240.
23. Leysen J.E., Janssen P.F., Janssen P.M., Heylen L., Gommeren W., Gompel P.v, Lesage A.S., Megens A.A., Schotte A. Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects. International Journal of Radiation Applications and Instruments. 2:1998;S3-S17.
24. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 17:1997;205-229.
25. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry. 151:1994;825-835.
26. Montgomery S.A., Åsberg A. A new depression scale designed to be sensitive to change. British Journal of Psychiatry. 134:1979;382-389.
27. Abnormal Involuntary Movement Scale (AIMS). Superintendent of Documents, 1974;US Government Printing Office, Washington, DC.
28. Nordström A.L., Nyberg S., Olsson H., Farde L. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Archives of General Psychiatry. 55:1998;283-284.
29. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. 16:1997;1-7.
30. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry. 166:1995;712-726.
31. 123I]IBZM single photon emission tomography (SPET) study. Psychopharmacology. 124:1996;148-153.
32. Seeman P., Kapur S. Clozapine occupies high levels of dopamine D2 receptors. Life Sciences. 60:1997;207-216.
33. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplementum. 212:1970;11-19.
34. 123I]IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology. 141:1999;175-181.
35. Tiihonen J., Kuoppamaki M., Nagren K., Bergman J., Eronen E., Syvalahti E., Hietala J. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology. 126(4):1996;277-280.
36. Tran P.V., Dellva M.A., Tollefson G.D., Beasley C.M.J., Potvin J.H., Kiesler G.M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry. 58:1997;205-211.
37. Travis M.J., Busatto G.F., Pilowsky L.S., Mulligan R., Acton P.D., Gacinovic S., Mertens J., Terriere D., Costa D.C., Ell P.J., Kerwin R.W. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine - a SPET study using the novel 5-HT2A ligand I-123-5-R-91150. British Journal of Psychiatry. 173:1998;236-241.
38. 123I]IBZM using the rotating gamma camera. Nuclear Medicine Communications. 12:1991;687-697.
39. 123I]IBZM in rat and human brain. International Journal of Radiation Application and Instruments. 18:1991;837-846.
40. 2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. Journal of Nuclear Medicine. 34:1993;2076-2084.
41. Volkow N.D., Wang G.J., Fowler J.S., Ding Y.S., Gur R.C., Gatley J., Logan J., Moberg P.J., Hitzemann R., Smith G., Pappas N. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Annals of Neurology. 44:1998;143-147.